Regulatory News :
As of January 31, 2013, shares and voting rights outstanding of Essilor
(Paris:EI), the world leader in ophthalmic optics, broke down as follows:
January 31, 2013
Exercisable voting rights
Total voting rights, based on all outstanding shares, including
shares stripped of their voting rights*
Shares held by the Company, either in treasury or under
the liquidity contract.
The world’s leading ophthalmic
optics company, Essilor designs, manufactures and markets a wide range
of lenses to improve and protect eyesight. Its corporate mission is to
enable everyone around the world to access lenses that meet his or her
unique vision requirements. To support this mission, the Company
allocates around €150 million to research and development every year, in
a commitment to continuously bring new, more effective products to
market. Essilor’s flagship brands are Varilux®,
Xperio®, Optifog™ and Foster Grant®.
It also develops and markets equipment, instruments and services for
Essilor reported consolidated revenue
of €4.2 billion in 2011 and employs around 48,700 people in some 100
countries. It operates 19 plants, a total of 390 prescription
laboratories and edging facilities, as well as several research and
development centers around the world.
For more information,
please visit www.essilor.com.
Essilor share trades on the NYSE Euronext Paris market and is included
in the CAC 40 and Euro Stoxx 50 indexes.
symbols:ISIN:FR0000121667; Reuters:ESSI.PA; Bloomberg:EI:FP.